Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen

Inclusion Criteria

• •1. Female patients with locally advanced breast cancer (stages IIB, IIIA and IIIB), confirmed anatomopathologically, with hormonal receptors (Estrogen and / or progesterone) and ERBB2 negative to the immunohistochemical study pattern.
• •2. Presence of measurable disease according to RECIST criteria.
• •3. Staging with chest X-ray, abdominal ultrasound and bone scintigraphy Without evidence of metastatic disease. Capture in bone scintigraphy should be Evaluated by simple radiographs.
• •4. Performance Status (PS) of Eastern Cooperative Oncology Group (ECOG) ≤ 2.
• •5. Adequate haematological function, evidenced by higher hemoglobin level Than 9 g / dl, neutrophil count greater than 1,500 / mm 3 and platelet count greater than 100,000 / mm 3.
• •6. Adequate liver function, evidenced by bilirubin levels below 1.5 of normal values and liver enzyme levels less than 2.5 times normal.
• •7. Adequate renal function, evidenced by creatinine levels lower than 1.5 times normal value and / or estimated creatinine clearance (Cockroft) greater than 50 ml / min.
• •8. Preserved cardiac function assessed by Doppler echocardiography.
• •9. Socio-cultural ability to understand a clinical study and the need to Attend regularly for medical examinations and appointments.